Search - tctmd.com

Displaying 101 - 120 of 120

Sort: Relevancy | Date

News Daily News

Tricky Population of Patients With A-fib Undergoing PCI Tackled in New Consensus Document

November 29, 2016

News Daily News

Avoid Simvastatin, Lovastatin in Dabigatran-Treated Patients, Analysis Suggests

November 24, 2016

News Conference News AHA 2016

Misdosing NOACs Common in Everyday Practice, With Implications for Stroke and Bleeding

November 21, 2016

News Conference News AHA 2016

Dabigatran Reversal Agent’s Safety, Efficacy Affirmed With Updated Study Results

November 15, 2016

News Conference News AHA 2016

Rivaroxaban-Based Double or Triple Therapy Cuts Bleeding in Patients With A-fib Undergoing PCI: PIONEER AF-PCI

November 14, 2016

News Daily News

Oral Anticoagulation Use Common in PCI Patients, With Triple Therapy the Norm at Discharge

October 18, 2016

News Daily News

More NOAC Comparisons See Higher Bleeding Risk With Rivaroxaban: Is the ‘Writing on the Wall’?

October 07, 2016

News Daily News

Low-Dose NOACs Top Warfarin in Asian Patients in Everyday Practice, Retrospective Study Suggests

September 26, 2016

News Daily News

Stroke Not the Only Concern in Patients With A-fib

September 07, 2016

News Conference News ESC 2016

Edoxaban Shows Safety, Efficacy for A-fib Patients Undergoing Cardioversion: ENSURE-AF

August 30, 2016

News Conference News ESC 2016

New ESC A-fib Guidelines Call for Integrated Care for All Patients

August 27, 2016

News Daily News

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

Michael O'Riordan

August 18, 2016

News Daily News

Warfarin Control Over Time Is Shaky Even in Those Who Are Initially Stable

August 10, 2016

News Daily News

Rivaroxaban May Help Dissolve Left Atrial Thrombus in Patients With A-fib

June 09, 2016

News Daily News

Good Warfarin Management Prevents Complications in A-fib Patients, Swedish Study Contends

April 21, 2016

News Industry News

Praxbind® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate)

November 29, 2015

News Industry News

CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa®)

September 25, 2015

News Daily News

Acute MI Arising From Coronary Embolism Rare, Often Tied to A-fib

July 08, 2015

News Industry News

Idarucizumab Reverses the Anticoagulant Effect of Dabigatran Within Minutes in Patient Study

June 22, 2015

News Industry News

One-Year Outcomes Data on Stroke Prevention in Patients With Newly Diagnosed Atrial Fibrillation (AF) to Be Presented at ISTH 2015

June 18, 2015

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.